Shots:

• The P-IIIa Dupixent Eosinophilic Esophagitis study involves assessing Dupixent (N=42) (300mg weekly) v/s PBO (N=39) in 81 patients aged 12 years and older with eosinophilic esophagitis (EoE). In addition- enrolling patients for P-IIIb for extended active treatment period to continue in 28wks
• The P-II study results: met its co-1EPs and 2EPs in DSQ baseline with reduction in disease symptoms (69% vs 32%)- EoE count reduction (60% vs 5%)
• Dupixent is a mAb to inhibit the signaling of IL-4 and IL-13 proteins and has received US FDA’s Orphan Drug Designation to treat EoE in 2017

Click here to read full press release/ article | Ref: Sanofi | Image: Behance